Evidence map›Paper›PMID 19259613›Full record

ArticleInternational journal of hematology2009

IL-6-induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33+ myeloma cells.

Karim Shamsasenjan, Ken-Ichiro Otsuyama, Saeid Abroun, Mohd S Iqbal, Maged S Mahmoud, Hideki Asaoku, Michio M Kawano

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. CD33 is downregulated by influenza virus H1N1pdm09 and induces ROS and the TNF-α, IL-1β, and IL-6 cytokines in human mononuclear cells.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Karim ShamsasenjanLaboratory of Cellular Signal Analysis, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-Kogushi, Ube, 755-8505, Japan.
Ken-Ichiro OtsuyamaLaboratory of Cellular Signal Analysis, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-Kogushi, Ube, 755-8505, Japan.
Saeid AbrounLaboratory of Cellular Signal Analysis, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-Kogushi, Ube, 755-8505, Japan.
Mohd S IqbalLaboratory of Cellular Signal Analysis, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-Kogushi, Ube, 755-8505, Japan.
Maged S MahmoudDepartment of Clinical Pathology, Assiut University Hospital, Assiut, Egypt.
Hideki AsaokuHiroshima Red Cross Hospital, Hiroshima, 730-0052, Japan.
Michio M KawanoLaboratory of Cellular Signal Analysis, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-Kogushi, Ube, 755-8505, Japan. mkawano@yamaguchi-u.ac.jp.
Yamaguchi University · JPAssiut University · EGJapanese Red Cross Hiroshima College of Nursing · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human myeloma cells from about 10% of cases with multiple myeloma expressed CD33 and had monocytoid morphology with convoluted nuclei, and all these patients had no increase in serum CRP values. In CD33(+) myeloma cells as well as myeloma cell lines, CD33 expression levels were correlated with the increased expression levels of CEBPA (C/EBPalpha). This correlation was confirmed by the finding that transfection with the CEBPA gene induced CD33 expression in a CD33(-) myeloma cell line. As suggested by the lack of an increase in serum CRP values in CD33(+) myelomas, IL-6 down-regulated the expression of CD33 in CD33(+) myeloma cell lines along with the down-regulation of CEBPA gene expression. Cucurbitacin I (STAT3 inhibitor), but not U0126 (MAPK inhibitor), could abolish the effect of IL-6. Furthermore, IL-6 up-regulated the expression of MYC via STAT3 phosphorylation and MYC bound to the promoter region of the CEBPA gene followed by the down-regulation of CEBPA expression. It was confirmed that introduction of shRNA for MYC into a CD33(+) myeloma cell line blocked the IL-6-induced down-regulation of CD33 and CEBPA expression. Therefore, these results indicate that IL-6 can reverse the expression level of CD33 by up-regulating MYC followed by the down-regulation of CEBPA expression.

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticCCAAT-Enhancer-Binding ProteinsDown-RegulationGene Expression Regulation, NeoplasticHumansInterleukin-6Multiple MyelomaPhosphorylationProto-Oncogene Proteins c-mycSialic Acid Binding Ig-like Lectin 3STAT3 Transcription FactorTumor Cells, CulturedAntigens, CDAntigens, Differentiation, MyelomonocyticCCAAT-Enhancer-Binding ProteinsCD33 protein, humanCEBPA protein, humanInterleukin-6Proto-Oncogene Proteins c-mycSialic Acid Binding Ig-like Lectin 3STAT3 protein, humanSTAT3 Transcription Factor

Identifiers

PMID19259613
OpenAlexW2024738237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.